Intelligence Feed event · Credit · 2026-10-19

    Viking Therapeutics raises $575M via equity and convertible notes

    Question

    Viking Therapeutics raises $575M via equity and convertible notes

    Direct answer

    Viking Therapeutics completed a $575 million capital raise utilizing a combination of equity and convertible senior notes. The liquidity injection is designated to support registration-directed Phase 3 clinical trials for its dual GLP-1/GIP receptor agonist VK2735. The transaction provides balance sheet runway through 2028, mitigating ongoing financing overhang ahead of pivotal readouts across 2027 and 2028. Equity desks anticipate typical convertible delta hedging, but operational solvency risk is removed for the next two years.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Viking Therapeutics raises $575M via equity and convertible notes”, revision 1, evidence through 2026-10-19. https://marketontology.com/market-events/2026-10-19/viking-therapeutics-raises-575m-via-equity-and-convertible-notes-3574ae

    CREDIT
    Viking Therapeutics raises $575M via equity and convertible notes
    Viking Therapeutics completed a $575 million capital raise utilizing a combination of equity and convertible senior notes. The liquidity injection is designated to support registration-directed Phase 3 clinical trials for its dual GLP-1/GIP receptor agonist VK2735. The transaction provides balance sheet runway through 2028, mitigating ongoing financing overhang ahead of pivotal readouts across 2027 and 2028. Equity desks anticipate typical convertible delta hedging, but operational solvency risk is removed for the next two years.
    VKTXXBI
    Impact
    69
    OCT 19
    SIG
    82%
    VKTXXBI
    Viking Therapeutics raises $575M via equity and convertible notes
    Viking Therapeutics completed a $575 million capital raise utilizing a combination of equity and convertible senior notes. The liquidity injection is designated to support registration-directed Phase 3 clinical trials for its dual GLP-1/GIP receptor agonist VK2735. The transaction provides balance sheet runway through 2028, mitigating ongoing financing overhang ahead of pivotal readouts across 2027 and 2028. Equity desks anticipate typical convertible delta hedging, but operational solvency risk is removed for the next two years.
    → A $575 million convertible debt and equity placement extends VKTX operational runway through 2028 while short-term delta hedging pressures equity float.
    Impact
    Viking Therapeutics completed a $575 million capital raise utilizing a combination of equity and convertible senior notes. The liquidity injection is designated to support registration-directed Phase 3 clinical trials for its dual GLP-1/GIP receptor agonist VK2735. The transaction provides balance sheet runway through 2028, mitigating ongoing financing overhang ahead of pivotal readouts across 2027 and 2028. Equity desks anticipate typical convertible delta hedging, but operational solvency risk is removed for the next two years.
    Affected
    VKTXXBI
    Transmission
    A $575 million convertible debt and equity placement extends VKTX operational runway through 2028 while short-term delta hedging pressures equity float.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    VKTXconvertible arbitrage delta hedging vs extended cash runwayMixed1-4w$575M raised in common stock and convertible notes to fund operations through 2028.
    XBIclinical biotech balance sheet de-riskingUp1-5dSuccessful large-scale liquidity event validates capital access for development-stage biotech.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month